Transforming Traws Pharma: A New Era with Luba Greenwood
Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company, has made a significant move by appointing Luba Greenwood to its Board of Directors. This exciting update signals an important evolution for Traws as it seeks to improve its capacity for developing groundbreaking therapies aimed at addressing respiratory viral diseases and cancer.
A Fresh Perspective on the Board
Luba Greenwood joins Traws at a crucial juncture as the company looks to advance its innovative pipeline. Iain Dukes, PhD, the Executive Chairman, shared his optimism regarding Greenwood's potential contributions. He remarked, "Luba's extensive experience and strategic insights in the biopharmaceutical field will be invaluable as we proceed with our Phase 1 studies for respiratory antiviral therapies and continue our oncology initiatives."
James J. Marino's Departure
As Traws welcomes Greenwood, it simultaneously bids farewell to James J. Marino, a Director who has invested nearly a decade into the company's growth. Marino's departure, after close to ten years, including a four-year term as Chairman, reflects a shift in his professional commitments. The Traws Board expressed sincere gratitude for his leadership and the significant contributions he provided during his tenure.
Luba Greenwood: A Proven Leader
Luba Greenwood is a highly regarded figure within the life sciences arena, known for her vast experience as a board member, investor, and executive. Currently, she is the Managing Partner at Binney Street Capital and has held key positions in several biopharmaceutical firms. Her skill in strategic development will be a tremendous asset to Traws as the company embarks on this new chapter of growth.
Navigating Forward
Greenwood shared her excitement about joining Traws during this transformative time. She noted the company’s strategic direction, particularly in light of its recent merger agreement, which bolsters its innovative framework. With a promising pipeline that features advanced initiatives for flu and COVID-19 therapies, Greenwood's insights will help reinforce Traws' commitment to tackling pressing healthcare challenges.
About Traws Pharma, Inc.
Traws Pharma is dedicated to developing small molecule therapies that address significant health challenges, particularly in respiratory and oncological fields. The company is actively working on two promising oral antiviral candidates that are currently in Phase 1 trials: tivoxavir marboxil and ratutrelvir. Both are engineered to effectively combat influenza and COVID-19.
Commitment to Advancing Healthcare
In oncology, Traws employs a collaborative approach to strengthen its research and development capabilities. The company continues to advance innovative options like narazaciclib, which targets specific pathways in cancer treatment, aiming to reshape the current landscape for cancer care.
Preparing for Clinical Success
Traws Pharma remains committed to improving drug development with a clear focus on unmet medical needs. Their dedication to safety and innovation positions them to significantly impact the treatment of viral infections and cancer, promising transformative outcomes for patients in need.
Frequently Asked Questions
Who is Luba Greenwood?
Luba Greenwood is an experienced executive in the life sciences sector, recently appointed to Traws Pharma's Board of Directors, focusing on biopharmaceutical advancements.
What does Traws Pharma primarily focus on?
Traws Pharma specializes in developing oral small molecule therapies aimed at treating respiratory viral diseases and cancer.
What key products are in Traws Pharma's pipeline?
Currently, Traws Pharma’s pipeline includes tivoxavir marboxil and ratutrelvir, both designed to target respiratory viral diseases.
What led to James J. Marino stepping down?
James J. Marino decided to step down from the Board after nearly ten years due to other professional commitments he was undertaking.
What is Luba Greenwood's expected role at Traws?
Luba Greenwood intends to utilize her strategic expertise to enhance Traws' growth and support its innovative therapies as the company progresses through clinical studies.
